Latest news with #GillesMartin
Yahoo
3 days ago
- Business
- Yahoo
Eurofins Scientific SE: Director/PDMR Shareholding
LUXEMBOURG, June 10, 2025--(BUSINESS WIRE)--Eurofins Scientific SE ( has received various notifications of dealing from Persons Discharging Managerial Responsibilities ("PDMR"). The notification of Dealing Form for each PDMR can be found below. This notification is made in accordance with the European Market Abuse Regulation. NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM 1. Details of the person discharging managerial responsibilities/person closely associated a) Name Analytical Bioventures S.C.A (RCS B89265)23, Va Fleuri, L-1526 Luxembourg 2. Reason for the notification a) Position / status Analytical Bioventures S.C.A. is a company controlled by Eurofins Scientific S.E., CEO Dr. Gilles Martin b) Initial notification / amendment Initial 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Eurofins Scientific S.E. b) LEI 529900JEHFM47DYY3S57 4. Details of the transaction(s) section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Share Identification code ISIN: FR0014000MR3 b) Nature of the transaction Acquisition of shares c) Price(s) and volume(s) Price(s) Volume(s) EUR 57.091200 2000 d) Aggregated information — Aggregated volume 2000 — Price EUR 114,182.40 e) Date of the transaction 2025-06-05 f) Place of the transaction XPAR NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM 1. Details of the person discharging managerial responsibilities/person closely associated a) Name Analytical Bioventures S.C.A (RCS B89265)23, Va Fleuri, L-1526 Luxembourg 2. Reason for the notification a) Position / status Analytical Bioventures S.C.A. is a company controlled by Eurofins Scientific S.E., CEO Dr. Gilles Martin b) Initial notification / amendment Initial 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Eurofins Scientific S.E. b) LEI 529900JEHFM47DYY3S57 4. Details of the transaction(s) section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Share Identification code ISIN: FR0014000MR3 b) Nature of the transaction Acquisition of shares c) Price(s) and volume(s) Price(s) Volume(s) EUR 57.375900 2000 d) Aggregated information — Aggregated volume 2000 — Price EUR 114,751.80 e) Date of the transaction 2025-06-06 f) Place of the transaction XPAR NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM 1. Details of the person discharging managerial responsibilities/person closely associated a) Name Analytical Bioventures S.C.A (RCS B89265)23, Va Fleuri, L-1526 Luxembourg 2. Reason for the notification a) Position / status Analytical Bioventures S.C.A. is a company controlled by Eurofins Scientific S.E., CEO Dr. Gilles Martin b) Initial notification / amendment Initial 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Eurofins Scientific S.E. b) LEI 529900JEHFM47DYY3S57 4. Details of the transaction(s) section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Share Identification code ISIN: FR0014000MR3 b) Nature of the transaction Acquisition of shares c) Price(s) and volume(s) Price(s) Volume(s) EUR 58.358800 2000 d) Aggregated information — Aggregated volume 2000 — Price EUR 116,117.60 e) Date of the transaction 2025-06-09 f) Place of the transaction XPAR For more information, please visit About Eurofins – the global leader in bio-analysis Eurofins is Testing for Life. With ca. 63,000 staff across a network of more than 950 laboratories in over 1,000 companies in 60 countries, Eurofins offers a portfolio of over 200,000 analytical methods. Eurofins Scientific S.E. shares are listed on Euronext Paris Stock Exchange. View source version on Contacts Investor RelationsEurofins Scientific SEPhone: +32 2 766 1620E-mail: ir@ Sign in to access your portfolio
Yahoo
15-05-2025
- Business
- Yahoo
Eurofins Scientific SE: Director/PDMR Shareholding
LUXEMBOURG, May 15, 2025--(BUSINESS WIRE)--Eurofins Scientific SE ( (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities ("PDMR"). The notification of Dealing Form for each PDMR can be found below. This notification is made in accordance with the European Market Abuse Regulation. NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM 1. Details of the person discharging managerial responsibilities/person closely associated a) Name Analytical Bioventures S.C.A (RCS B89265)23, Va Fleuri, L-1526 Luxembourg 2. Reason for the notification a) Position / status Analytical Bioventures S.C.A. is a company controlled by Eurofins Scientific S.E., CEO Dr. Gilles Martin b) Initial notification / amendment Initial 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Eurofins Scientific S.E. b) LEI 529900JEHFM47DYY3S57 4. Details of the transaction(s) section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Share Identification code ISIN: FR0014000MR3 b) Nature of the transaction Acquisition of shares c) Price(s) and volume(s) Price(s) Volume(s) EUR 56.034800 2000 d) Aggregated information — Aggregated volume 2000 — Price EUR 112,069.60 e) Date of the transaction 2025-05-13 f) Place of the transaction XPAR NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM 1. Details of the person discharging managerial responsibilities/person closely associated a) Name Analytical Bioventures S.C.A (RCS B89265)23, Va Fleuri, L-1526 Luxembourg 2. Reason for the notification a) Position / status Analytical Bioventures S.C.A. is a company controlled by Eurofins Scientific S.E., CEO Dr. Gilles Martin b) Initial notification / amendment Initial 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Eurofins Scientific S.E. b) LEI 529900JEHFM47DYY3S57 4. Details of the transaction(s) section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Share Identification code ISIN: FR0014000MR3 b) Nature of the transaction Acquisition of shares c) Price(s) and volume(s) Price(s) Volume(s) EUR 54.564900 4000 d) Aggregated information — Aggregated volume 4000 — Price EUR 218,259.60 e) Date of the transaction 2025-05-14 f) Place of the transaction XPAR About Eurofins – the global leader in bio-analysis Eurofins is Testing for Life. With ca. 63,000 staff across a network of more than 950 laboratories in over 1,000 companies in 60 countries, Eurofins offers a portfolio of over 200,000 analytical Scientific S.E. shares are listed on Euronext Paris Stock Exchange. View source version on Contacts For more information, please visit or contact: Investor RelationsEurofins Scientific SEPhone: +32 2 766 1620E-mail: ir@
Yahoo
13-05-2025
- Business
- Yahoo
Eurofins Scientific: Director/PDMR Shareholding
LUXEMBOURG, May 13, 2025--(BUSINESS WIRE)--Eurofins Scientific SE ( has received various notifications of dealing from Persons Discharging Managerial Responsibilities ("PDMR"). The notification of Dealing Form for each PDMR can be found below. This notification is made in accordance with the European Market Abuse Regulation. NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM 1. Details of the person discharging managerial responsibilities/person closely associated a) Name Analytical Bioventures S.C.A (RCS B89265)23, Va Fleuri, L-1526 Luxembourg 2. Reason for the notification a) Position / status Analytical Bioventures S.C.A. is a company controlled by Eurofins Scientific S.E., CEO Dr. Gilles Martin b) Initial notification / amendment Initial 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Eurofins Scientific S.E. b) LEI 529900JEHFM47DYY3S57 4. Details of the transaction(s) section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Share Identification code ISIN: FR0014000MR3 b) Nature of the transaction Acquisition of shares c) Price(s) and volume(s) Price(s) Volume(s) EUR 56.514200 2000 d) Aggregated information — Aggregated volume 2000 — Price EUR 113,028.40 e) Date of the transaction 2025-05-09 f) Place of the transaction XPAR NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM 1. Details of the person discharging managerial responsibilities/person closely associated a) Name Analytical Bioventures S.C.A (RCS B89265)23, Va Fleuri, L-1526 Luxembourg 2. Reason for the notification a) Position / status Analytical Bioventures S.C.A. is a company controlled by Eurofins Scientific S.E., CEO Dr. Gilles Martin b) Initial notification / amendment Initial 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Eurofins Scientific S.E. b) LEI 529900JEHFM47DYY3S57 4. Details of the transaction(s) section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Share Identification code ISIN: FR0014000MR3 b) Nature of the transaction Acquisition of shares c) Price(s) and volume(s) Price(s) Volume(s) EUR 55.792600 2000 d) Aggregated information — Aggregated volume 2000 — Price EUR 111,585.20 e) Date of the transaction 2025-05-12 f) Place of the transaction XPAR For more information, please visit About Eurofins – the global leader in bio-analysis Eurofins is Testing for Life. With ca. 63,000 staff across a network of more than 950 laboratories in over 1,000 companies in 60 countries, Eurofins offers a portfolio of over 200,000 analytical methods. Eurofins Scientific S.E. shares are listed on Euronext Paris Stock Exchange. View source version on Contacts Investor RelationsEurofins Scientific SEPhone: +32 2 766 1620E-mail: ir@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
01-04-2025
- Business
- Yahoo
Eurofins Announces the Successful Closing of Its Acquisition of SYNLAB's Clinical Diagnostics Operations in Spain
LUXEMBOURG, April 01, 2025--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific ( a global scientific leader in bioanalytical testing, with a rapidly developing presence in highly specialised and molecular clinical diagnostics testing and in-vitro diagnostics products, announces the successful closing of the acquisition of SYNLAB's clinical diagnostics operations in Spain and the transfer of operations to Eurofins, which took place on 31 March 2025. SYNLAB's clinical diagnostics operations in Spain comprise clinical diagnostics testing services, including genetics and anatomical pathology services, provided throughout the country, achieving revenues of approximately €140m in 2024. SYNLAB's operations strongly complement the Eurofins network's existing clinical diagnostics operations in Spain, led by Eurofins Megalab, a specialist in all types of clinical diagnostics testing and in managing intra-hospital laboratories in Spain. With this acquisition, Eurofins will become a leading clinical diagnostics operator in Spain, with a unique capability to cater to public and private clients and cover all regions in the country. The extensive network of Eurofins clinical diagnostics laboratories and blood collection points will have the capacity to serve more than 10 million patients and process over 100 million laboratory tests annually. Employing a highly specialised workforce of over 2,000 staff and a best-in-class portfolio of clinical diagnostics laboratory tests, Eurofins is capable of providing high-quality services based on the latest technology and scientific medical advances. Comment from Dr Gilles Martin, Eurofins CEO: "We are pleased to welcome SYNLAB's Spanish clinical diagnostics team to Eurofins. With our newly expanded network, we will be able to provide an even greater service offering to our clients, to whom we are a trusted, technologically advanced partner". Notes to Editors: About Eurofins – the global leader in bio-analysis Eurofins is Testing for Life. The Eurofins Scientific SE network of independent companies believes that it is a global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced material sciences and agroscience contract research services. It is also one of the market leaders in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in biopharma contract development and manufacturing. It also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products. With ca. 63,000 staff across a decentralised and entrepreneurial network of more than 950 laboratories in over 1,000 companies in 60 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products. Eurofins companies' broad range of services are important for the health and safety of people and our planet. The ongoing investment to become fully digital and maintain the best network of state-of-the-art laboratories and equipment supports our objective to provide our customers with high-quality services, innovative solutions and accurate results in the best possible turnaround time (TAT). Eurofins companies are well positioned to support clients' increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the evolving requirements of healthcare practitioners around the world. The Eurofins network has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, its companies draw on the latest developments in the field of biotechnology and analytical chemistry to offer their clients unique analytical solutions. Shares in Eurofins Scientific SE are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters Bloomberg ERF FP). Until it has been lawfully made public widely by Eurofins Scientific SE through approved distribution channels, this document contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended. Important disclaimer: This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific SE's management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific SE disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company's management as of the date of publication, but no guarantees can be made as to their completeness or validity. View source version on Contacts For more information, please visit or contact: Investor RelationsEurofins Scientific SEPhone: +32 2 766 1620E-mail: ir@ Sign in to access your portfolio
Yahoo
28-03-2025
- Business
- Yahoo
Eurofins Successfully Prices New Hybrid Bonds of €400m
LUXEMBOURG, March 27, 2025--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF): Eurofins Scientific ( rated Baa3 by Moody's and BBB- by Fitch), a global leader in bioanalytical testing, announces that it has successfully raised €400m in its latest Euro hybrid bond public issuance. The transaction was well received and more than 3x times over-subscribed. This new series of bonds has no specified maturity date and is accounted for as 100% equity according to international financial reporting standards (IFRS) and 50% equity with the rating agencies Moody's and Fitch. It will bear a fixed annual coupon of 5.75% for the first 7 years (until 4 April 2032) with a first call date on 4 January 2032, upon which date Eurofins can elect to repay the bonds. This issuance enables Eurofins to maintain its targeted capital structure that includes an adequate level of hybrid capital of €1bn to support its targeted range of financial leverage of 1.5-2.5x. The bonds' proceeds can be used for the repayment of the hybrid bonds (ISIN: XS1716945586) callable on 13 November 2025, and currently under a tender offer until 02 April 2025 inclusive, as well as for general corporate purposes. Outside of the planned repayment of Schuldschein loans, totalling €234m maturing in July and October 2025, Eurofins has no major refinancing requirements until the outstanding €302m senior Eurobonds become due for repayment on 17 July 2026. Comment from Dr Gilles Martin, Eurofins CEO: "The successful issuance of our new €400m hybrid bond reinforces Eurofins' strong balance sheet and confirms investor confidence in Eurofins' profitability and cash flow growth trends." The bonds will be listed from their issue date (4 April 2025) on the regulated market of the Luxembourg stock exchange (ISIN XS3038659267). The bonds are not registered under the US Securities Act of 1933 as amended (the "Securities Act"), and may not be offered or sold in (i) the United States (as such term is defined in Regulation S under the Securities Act) unless registered under the Securities Act or pursuant to an exemption from such registration nor (ii) in any other jurisdiction where it is unlawful to do so. Notes to Editors: About Eurofins – the global leader in bio-analysis Eurofins is Testing for Life. The Eurofins Scientific SE network of independent companies believes that it is a global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced material sciences and agroscience contract research services. It is also one of the market leaders in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in biopharma contract development and manufacturing. It also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products. With ca. 63,000 staff across a decentralised and entrepreneurial network of more than 950 laboratories in over 1,000 companies in 60 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products. Eurofins companies' broad range of services are important for the health and safety of people and our planet. The ongoing investment to become fully digital and maintain the best network of state-of-the-art laboratories and equipment supports our objective to provide our customers with high-quality services, innovative solutions and accurate results in the best possible turnaround time (TAT). Eurofins companies are well positioned to support clients' increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the evolving requirements of healthcare practitioners around the world. The Eurofins network has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, its companies draw on the latest developments in the field of biotechnology and analytical chemistry to offer their clients unique analytical solutions. Shares in Eurofins Scientific SE are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters Bloomberg ERF FP). Until it has been lawfully made public widely by Eurofins Scientific SE through approved distribution channels, this document contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended. Important disclaimer: This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific SE's management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific SE disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company's management as of the date of publication, but no guarantees can be made as to their completeness or validity. View source version on Contacts For more information, please visit or contact: Investor RelationsEurofins Scientific SEPhone: +32 2 766 1620E-mail: ir@
